TapewireFind a company

person · Reporting owner

Delaet Ingrid

Disclosed activity across 1 company

Tapewire entity
30877
SEC CIK
0001965808

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655Chief Regulatory OfficerSeptember 11, 2026September 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEUROCRINE BIOSCIENCES INC

Report date September 11, 2026 · Filed September 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect18,289 Ending reported balance After 2026-09-11 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-09-11 · Grant · Acquired 4,483 · Balance 20,708

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

Row 2 · 2026-09-11 · Tax withholding · Disposed 2,419 · Balance 18,289

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 31, 2024 Filed Jan 3, 2025 21:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 272 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,718

Underlying: Common Stock · 272 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 272 $138.10 $37,563.20
Disclosure

SEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 272 $79.02 $21,493.44
Disclosure

SEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 17, 2024 Filed Dec 19, 2024 21:37 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 1,091 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,990

Underlying: Common Stock · 1,091 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
December 17, 2024 Filed Dec 19, 2024 21:37 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,091 $135.00 $147,285.00
Disclosure

SEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

Read SEC document
December 17, 2024 Filed Dec 19, 2024 21:37 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 1,091 $79.02 $86,210.82
Disclosure

SEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:06 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 3,043 $0.00 Strike: $103.52 $0.00
Disclosure

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · derivative · entry 4

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,049

Underlying: Common Stock · 3,043 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:06 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 4,100 $150.08 $615,333.33
Disclosure

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:06 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,043 $150.13 $456,847.11
Disclosure

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,607

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 13, 2024 Filed Aug 15, 2024 21:06 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 3,043 $103.52 $315,011.36
Disclosure

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 06, 2024 Filed Aug 8, 2024 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 273 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,081

Underlying: Common Stock · 273 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
August 06, 2024 Filed Aug 8, 2024 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 273 $147.70 $40,322.10
Disclosure

SEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,607

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

Read SEC document
August 06, 2024 Filed Aug 8, 2024 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 273 $79.02 $21,572.46
Disclosure

SEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 1,557 $0.00 Strike: $103.52 $0.00
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · derivative · entry 7

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,092

Underlying: Common Stock · 1,557 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 400 $0.00 Strike: $103.52 $0.00
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · derivative · entry 6

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,649

Underlying: Common Stock · 400 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 900 $150.04 $135,036.00
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 5

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,607

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,557 $150.00 $233,550.00
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 4

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 1,557 $103.52 $161,180.64
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 400 $150.10 $60,041.00
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.05 to $150.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
July 16, 2024 Filed Jul 18, 2024 21:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 400 $103.52 $41,408.00
Disclosure

SEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,907

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 01:09 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 272 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-24-000164 · wk-form4_1719968973.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,354

Underlying: Common Stock · 272 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 01:09 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 272 $138.11 $37,565.92
Disclosure

SEC source: 0000914475-24-000164 · wk-form4_1719968973.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

Read SEC document
July 01, 2024 Filed Jul 3, 2024 01:09 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 272 $79.02 $21,493.44
Disclosure

SEC source: 0000914475-24-000164 · wk-form4_1719968973.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 31, 2024 Filed Jun 4, 2024 20:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 273 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0000914475-24-000162 · wk-form4_1717532582.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,626

Underlying: Common Stock · 273 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
May 31, 2024 Filed Jun 4, 2024 20:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 273 $136.55 $37,278.15
Disclosure

SEC source: 0000914475-24-000162 · wk-form4_1717532582.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

Read SEC document
May 31, 2024 Filed Jun 4, 2024 20:23 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 273 $79.02 $21,572.46
Disclosure

SEC source: 0000914475-24-000162 · wk-form4_1717532582.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 06, 2024 Filed May 8, 2024 20:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 273 $79.02 Strike: $79.02 $21,572.46
Disclosure

SEC source: 0000914475-24-000119 · wk-form4_1715200000.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,899

Underlying: Common Stock · 273 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
May 06, 2024 Filed May 8, 2024 20:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 273 $140.55 $38,370.15
Disclosure

SEC source: 0000914475-24-000119 · wk-form4_1715200000.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

Read SEC document
May 06, 2024 Filed May 8, 2024 20:26 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 273 $79.02 $21,572.46
Disclosure

SEC source: 0000914475-24-000119 · wk-form4_1715200000.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 20:44 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 272 $79.02 Strike: $79.02 $21,493.44
Disclosure

SEC source: 0000914475-24-000100 · wk-form4_1712177026.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,172

Underlying: Common Stock · 272 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 20:44 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 272 $137.30 $37,345.60
Disclosure

SEC source: 0000914475-24-000100 · wk-form4_1712177026.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
April 01, 2024 Filed Apr 3, 2024 20:44 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 272 $79.02 $21,493.44
Disclosure

SEC source: 0000914475-24-000100 · wk-form4_1712177026.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 21, 2024 Filed Mar 25, 2024 22:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 5,000 $103.52 Strike: $103.52 $517,600.00
Disclosure

SEC source: 0000914475-24-000098 · wk-form4_1711404161.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,049

Underlying: Common Stock · 5,000 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
March 21, 2024 Filed Mar 25, 2024 22:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 5,000 $145.06 $725,320.00
Disclosure

SEC source: 0000914475-24-000098 · wk-form4_1711404161.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Transactions at prices ranging from $145.00 to $145.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 21, 2024 Filed Mar 25, 2024 22:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 5,000 $103.52 $517,600.00
Disclosure

SEC source: 0000914475-24-000098 · wk-form4_1711404161.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 13, 2024 Filed Mar 15, 2024 21:15 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 3,000 $106.02 Strike: $106.02 $318,060.00
Disclosure

SEC source: 0000914475-24-000090 · wk-form4_1710537319.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,367

Underlying: Common Stock · 3,000 shares

Expires 2031-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022.

Read SEC document
March 13, 2024 Filed Mar 15, 2024 21:15 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,000 $140.14 $420,419.40
Disclosure

SEC source: 0000914475-24-000090 · wk-form4_1710537319.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 13, 2024 Filed Mar 15, 2024 21:15 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 3,000 $106.02 $318,060.00
Disclosure

SEC source: 0000914475-24-000090 · wk-form4_1710537319.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 11, 2024 Filed Mar 12, 2024 22:38 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 200 $106.02 Strike: $106.02 $21,204.00
Disclosure

SEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · derivative · entry 6

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,367

Underlying: Common Stock · 200 shares

Expires 2031-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022.

Read SEC document
March 11, 2024 Filed Mar 12, 2024 22:38 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 200 $140.00 $28,000.00
Disclosure

SEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 4

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
March 11, 2024 Filed Mar 12, 2024 22:38 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 200 $106.02 $21,204.00
Disclosure

SEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,707

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 08, 2024 Filed Mar 12, 2024 22:38 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 1,800 $106.02 Strike: $106.02 $190,836.00
Disclosure

SEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · derivative · entry 5

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,567

Underlying: Common Stock · 1,800 shares

Expires 2031-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022.

Read SEC document
March 08, 2024 Filed Mar 12, 2024 22:38 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 1,800 $140.03 $252,052.56
Disclosure

SEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 08, 2024 Filed Mar 12, 2024 22:38 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 1,800 $106.02 $190,836.00
Disclosure

SEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 00:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 273 $79.02 Strike: $79.02 $21,572.46
Disclosure

SEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 12

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,444

Underlying: Common Stock · 273 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 00:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 273 $135.51 $36,994.23
Disclosure

SEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 8

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 00:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 273 $79.02 $21,572.46
Disclosure

SEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 7

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 00:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 1,544 $79.02 Strike: $79.02 $122,006.88
Disclosure

SEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 11

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,717

Underlying: Common Stock · 1,544 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 00:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 2,500 $79.02 Strike: $79.02 $197,550.00
Disclosure

SEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 10

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,261

Underlying: Common Stock · 2,500 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 00:02 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 2,500 $79.02 Strike: $79.02 $197,550.00
Disclosure

SEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 9

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,761

Underlying: Common Stock · 2,500 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.